Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hematologic Malignancies

Hematologic Malignancies

Part of Cancer

Subtypes of Hematologic Malignancies

Hematological malignancies 12 Hematological Malignancy 3 Polycythemia Vera 2

26 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hematologic Malignancies

29 trials tracked for Hematologic Malignancies: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 453 citations.

29Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 2 Phase 2 20 Phase 1 4 Other / NA 3
  1. Phase 3 Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma Completed · 453 cited
  2. Phase 3 Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) Completed
  3. Phase 2 Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT Completed
  4. Phase 2 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant Completed
  5. Phase 2 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Completed
  6. Phase 2 A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders Completed
Show 23 more trials
  1. Phase 2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Completed
  2. Phase 2 Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen Completed
  3. Phase 2 Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Completed
  4. Phase 2 Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies Completed
  5. Phase 2 A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies Completed
  6. Phase 2 A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative Completed
  7. Phase 2 Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support Completed
  8. Phase 2 Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation Completed
  9. Phase 2 Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation Completed
  10. Phase 2 Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation Completed
  11. Phase 2 Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease Completed
  12. Phase 2 Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy Completed
  13. Phase 2 Phase II Trial of Pentostatin and Targeted Busulfan Completed
  14. Phase 2 Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide Completed
  15. Phase 2 Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies Completed
  16. Phase 2 Cytokine Induced Killer (CIK) Cells In Leukemia Patients Completed
  17. Phase 1 Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies Completed
  18. Phase 1 Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction Completed
  19. Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment Completed
  20. Phase 1 A Study Of PF-04449913 In Select Hematologic Malignancies Completed
  21. N/A An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies Completed
  22. N/A Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies Completed
  23. N/A Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Hematologic Malignancies: what the trials found

In the management of hematologic malignancies, Denosumab has been shown to significantly improve time to first on-study skeletal related events compared to standard care (p=0.010) 4. Other established interventions include the use of Cyclophosphamide [10, 11], Posaconazole 5, and Pentostatin 17. Specifically, trials involving Pentostatin reported a progression-free survival rate of 55% and an overall survival rate of 68% 17. Additionally, evidence suggests that the addition of photopheresis to Pentostatin for allogeneic stem cell transplantation resulted in a lower incidence of Grade 2-4 acute graft versus host disease (GVHD) compared to no photopheresis 15.

Recent results — preliminary, needs further review

  • • CC-486 was evaluated in a Phase 2 trial 1.
  • • Fludarabine showed favorable outcomes for 6-month probability of survival as assessed by absence of Grade III-IV GVHD or graft failure, with zero cases of acute Grade III-IV GVHD reported 2.
  • • An inpatient serious illness care program was evaluated in a Phase N/A trial 3.
  • • Tildrakizumab was evaluated in a Phase 2 trial 6.

For the clinician treating this condition

  • Denosumab is associated with a statistically significant increase in time to first skeletal related events 4.
  • Pentostatin has been associated with an overall survival rate of 68% and progression-free survival of 55% 17.
  • Photopheresis combined with Pentostatin was associated with lower rates of Grade 2-4 acute GVHD compared to no photopheresis 15.

AI synthesis of 8 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Andrographolide induces apoptosis and ferroptosis in hematological malignancies through ROS-dependent pathways
Drug Pipeline Sys. Review
Andrographolide induces apoptosis and ferroptosis in hematological malignancies through ROS-dependent pathways Andrographolide shows promise against certain blood cancers in early research
This narrative review synthesizes preclinical evidence regarding the mechanisms of andrographolide in hematological malignancies. The review…
Early laboratory tests suggest a compound called andrographolide may help stop the growth of certain blood cancer cells.
Frontiers Oct 16, 2026
Extended rhythm monitoring identifies 64% of asymptomatic atrial fibrillation in patients on BTKi therapy
Cardiology Meta-analysis
Extended rhythm monitoring identifies 64% of asymptomatic atrial fibrillation in patients on BTKi therapy BTK Inhibitors Linked to Hidden Heart Rhythm Problem in Cancer Patients
This meta-analysis of 2839 patients with hematologic malignancies treated with Bruton's tyrosine kinase inhibitors (BTKi) found an overall a…
A meta-analysis of 2,839 patients found that 14% of atrial fibrillation cases during BTK inhibitor therapy had no symptoms.
Oct 2, 2026
Ropeginterferon alfa-2b increases complete hematologic response from 26% to 59% in polycythemia vera
Drug Pipeline Meta-analysis
Ropeginterferon alfa-2b increases complete hematologic response from 26% to 59% in polycythemia vera Ropeginterferon alfa-2b shows promise for patients with polycythemia vera
This meta-analysis of 1,836 patients with myeloproliferative neoplasms found that ropeginterferon alfa-2b increases complete hematologic res…
New data shows ropeginterferon alfa-2b helps many patients with polycythemia vera achieve better blood counts and lower disease markers over…
Frontiers Sep 24, 2026
B-cell depletion and S1P inhibitors significantly reduce mRNA vaccine binding antibody levels in immunocompromised patients
Infectious Disease Meta-analysis
B-cell depletion and S1P inhibitors significantly reduce mRNA vaccine binding antibody levels in immunocompromised patients Immune treatments significantly lower antibody levels from mRNA vaccines
This meta-analysis evaluates mRNA vaccine binding antibody levels in patients receiving B-cell depletion, S1P inhibitors, or JAK inhibitors.…
Certain immune-suppressing medications significantly lower the amount of antibodies produced after mRNA vaccination, impacting protection le…
medRxiv Sep 23, 2026
Busulfan-based conditioning favors survival in AML while TBI yields better outcomes in ALL
Pediatrics Meta-analysis
Busulfan-based conditioning favors survival in AML while TBI yields better outcomes in ALL Busulfan Shows Survival Benefits for Patients with Acute Myeloid Leukemia
This meta-analysis of 26 studies compared Busulfan-based conditioning to total body irradiation for children and young adults undergoing hem…
Busulfan may offer better survival for certain leukemias while reducing long-term side effects like growth issues and cataracts in young pat…
Frontiers Sep 17, 2026
Cryopreserved PBMC starting material is a feasible approach for CAR-T cell manufacturing in hematological malignancies
Allergy & Immunology Meta-analysis
Cryopreserved PBMC starting material is a feasible approach for CAR-T cell manufacturing in hematological malignancies Cryopreserved Cells Show Potential for CAR-T Cell Manufacturing
This systematic review evaluates the impact of cryopreserved versus fresh PBMC starting materials on CAR-T cell manufacturing outcomes. The …
Frozen blood cells may work as a viable starting material for CAR-T cell therapy, showing similar expansion and activity to fresh cells.
Frontiers Sep 3, 2026
Approximately 61% of cancer patients resume anticancer treatment after unplanned ICU admission
Oncology Meta-analysis
Approximately 61% of cancer patients resume anticancer treatment after unplanned ICU admission Most cancer patients do not resume treatment after ICU stay
This meta-analysis of 3551 patients with solid tumors or hematological malignancies found that 61% of patients resumed any anticancer treatm…
Only about 60% of cancer patients resume any treatment after an unplanned ICU stay, highlighting a critical gap in care after a medical cris…
Sep 2, 2026
High CAR-HEMATOTOX scores correlate with increased ICAHT odds and worse survival in CAR T-cell therapy
Oncology Meta-analysis
High CAR-HEMATOTOX scores correlate with increased ICAHT odds and worse survival in CAR T-cell therapy New Risk Score Identifies Complications in CAR T-cell Therapy
This meta-analysis evaluates the CAR-HEMATOTOX score as a risk-stratification tool for patients receiving CAR T-cell therapy for hematologic…
A new scoring tool helps identify patients at higher risk for severe complications and infections during CAR T-cell therapy for blood cancer…
Frontiers Sep 2, 2026
Tocilizumab serves as first-line therapy for CRS in CAR-T and VST cellular immunotherapies
Diabetes & Endocrinology Guideline
Tocilizumab serves as first-line therapy for CRS in CAR-T and VST cellular immunotherapies New guidelines offer clear paths for managing CAR-T cell complications
This clinical guideline provides a framework for managing early complications in patients receiving CAR-T cell or virus-specific T-lymphocyt…
New clinical guidelines provide clear steps for managing serious side effects like cytokine release syndrome in patients receiving CAR-T cel…
Frontiers Aug 29, 2026
Ropeginterferon alfa-2b shows significant benefit over phlebotomy for complete hematologic response in polycythemia vera
Oncology Meta-analysis
Ropeginterferon alfa-2b shows significant benefit over phlebotomy for complete hematologic response in polycythemia vera Ropeginterferon alfa-2b shows better results than phlebotomy for PV
This meta-analysis of 522 patients with polycythemia vera found that ropeginterferon alfa-2b provides a statistically significant advantage …
A new analysis shows that ropeginterferon alfa-2b may offer better long-term management for polycythemia vera patients compared to standard …
NEJM Aug 9, 2026
Elevated serum ferritin is associated with increased mortality risk in patients with malignant tumors
Oncology Meta-analysis
Elevated serum ferritin is associated with increased mortality risk in patients with malignant tumors High Serum Ferritin Levels Linked to Higher Mortality Risk
This meta-analysis of 3,083 adult patients found that elevated serum ferritin (SF) significantly correlates with higher mortality risk. An e…
A large review of over 3,000 patients found that high serum ferritin levels are linked to a higher risk of death in certain types of cancer.
Frontiers Aug 5, 2026
TET2 functions as a tumor suppressor in myeloid malignancies and immunomodulator in solid tumors
Rheumatology Sys. Review
TET2 functions as a tumor suppressor in myeloid malignancies and immunomodulator in solid tumors TET2 protein acts as a key regulator in several diseases
This systematic review examines the role of TET2 across various conditions including hematological malignancies, solid tumors, and inflammat…
A key protein called TET2 helps control cell behavior and may play a major role in treating cancer and inflammatory conditions.
Frontiers Aug 4, 2026

Questions about Hematologic Malignancies

Are T cell-based therapies like CAR-T effective for treating hematologic malignancies?

Yes, CAR-T cell therapy is highly effective for hematologic malignancies, with success in blood cancers like ALL, but faces challenges in solid tumors.

Full answer →

All Hematologic Malignancies Articles